Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs

Hospices Civils de Lyon38 enrolled

Overview

Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related Problems (DRPs), and re-hospitalizations. This study aims to evaluate the impact of a multidisciplinary city-hospital follow-up program on medication management safety in haematological oncology patients receiving intravenous chemotherapy in onco-haematology. Additional aspects will be evaluated, such as the impact of the follow-up on the city-hospital link, satisfaction of patients and professionals involved in the follow-up and the use of telecare

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chemotherapy Effect G-CHOP Chemotherapy R-CHOP Chemotherapy

Interventions

Assessment of patient satisfaction regarding tele-consultation

Questionnaire completed following the teleconsultation, if applicable.

Literacy questionnaireOTHER

Questionnaire completed during hospitalization for the first chemotherapy cycle

Collection of socio-demographic characteristicsOTHER

Questionnaire completed during patient hospitalization for the first chemotherapy cycle

Assessment of patient knowledge on chemotherapy side effects and support medicationsOTHER

Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy

Assessment of patient satisfaction on pharmaceutical follow-upOTHER

Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Adult patients aged 18 years or older With hematological malignancy at any stage Initiating R-CHOP or G-CHOP chemotherapy Who do not object to participation in the study and use of collected data Exclusion Criteria: * Patients already enrolled in a clinical trial evaluating any drug product * Patients living in an institution * Patients protected by law * Adults subject to a legal protection measure (curatorship, guardianship) (article L1121-8 of the CSP) * Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social establishment (article L1121-6 of the CSP)

Locations (1)

Hôpital Lyon Sud - Hospices Civils de lyon

Pierre-Bénite, France

Outcomes

Primary Outcomes

Evaluation of the clinical impact of pharmacist interventions at first cycle of chemotherapy, according to the CLEO© scale.

Each pharmacist intervention performed during patient follow-up will be rated according to its expected level of clinic impact (major, moderate, minor, null)

Time frame: 6 months after inclusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.